ABIOMED (ABMD) : Essex Woodlands Health Ventures reduced its stake in ABIOMED by 32.56% during the most recent quarter end. The investment management company now holds a total of 1,450,000 shares of ABIOMED which is valued at $136.4 Million after selling 700,000 shares in ABIOMED , the firm said in a disclosure report filed with the SEC on May 12, 2016.ABIOMED makes up approximately 37.75% of Essex Woodlands Health Ventures’s portfolio.
Other Hedge Funds, Including , Coe Capital Management reduced its stake in ABMD by selling 66,272 shares or 77.7% in the most recent quarter. The Hedge Fund company now holds 19,021 shares of ABMD which is valued at $1.8 Million. ABIOMED makes up approx 0.57% of Coe Capital Management’s portfolio. Financial Architects Inc added ABMD to its portfolio by purchasing 2,000 company shares during the most recent quarter which is valued at $188,160. ABIOMED makes up approx 0.07% of Financial Architects Inc’s portfolio.Stephens Investment Management Group boosted its stake in ABMD in the latest quarter, The investment management firm added 23,550 additional shares and now holds a total of 264,105 shares of ABIOMED which is valued at $25.1 Million. ABIOMED makes up approx 0.88% of Stephens Investment Management Group’s portfolio.Old Mutual Global Investors (uk) Ltd. reduced its stake in ABMD by selling 38,056 shares or 20.77% in the most recent quarter. The Hedge Fund company now holds 145,127 shares of ABMD which is valued at $13.8 Million. ABIOMED makes up approx 0.28% of Old Mutual Global Investors (uk) Ltd.’s portfolio.Hanseatic Management Services Inc reduced its stake in ABMD by selling 779 shares or 2.97% in the most recent quarter. The Hedge Fund company now holds 25,463 shares of ABMD which is valued at $2.4 Million. ABIOMED makes up approx 0.88% of Hanseatic Management Services Inc’s portfolio.
ABIOMED opened for trading at $96 and hit $97.32 on the upside on Friday, eventually ending the session at $97.28, with a gain of 2.01% or 1.92 points. The heightened volatility saw the trading volume jump to 3,90,928 shares. Company has a market cap of $4,143,739 M.
On the company’s financial health, ABIOMED reported $0.24 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.18. The company had revenue of $94.00 million for the quarter, compared to analysts expectations of $90.46 million. The company’s revenue was up 39.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.24 EPS.
Abiomed Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company’s products include Impella 2.5 a percutaneous micro heart pump with an integrated motor and sensors; Impella CP which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000 a circulatory support system for the temporary support of acute heart failure patients in profound shock and Symphony a minimally invasive implantable cardiac assist device.